BioCentury
ARTICLE | Clinical News

iCo-007: Completed Phase II enrollment

June 24, 2013 7:00 AM UTC

iCo said investigators completed enrollment in the U.S. Phase II iDEAL trial to evaluate intravitreal injections of 350 and 700 µg iCo-007 alone and in combination with laser photocoagulation or ranib...